Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Diabetes Mellitus and Risk of Hepatocellular Carcinoma.

Li X, Wang X, Gao P.

Biomed Res Int. 2017;2017:5202684. doi: 10.1155/2017/5202684. Epub 2017 Dec 12. Review.

2.

Risk of Cardiovascular Disease Due to Chronic Hepatitis C Infection: A Review.

Babiker A, Jeudy J, Kligerman S, Khambaty M, Shah A, Bagchi S.

J Clin Transl Hepatol. 2017 Dec 28;5(4):343-362. doi: 10.14218/JCTH.2017.00021. Epub 2017 Aug 31. Review.

3.

Risk of Acute Myocardial Infarction Among Hepatitis C Virus (HCV)-Positive and HCV-Negative Men at Various Lipid Levels: Results From ERCHIVES.

Butt AA, Yan P, Chew KW, Currier J, Corey K, Chung RT, Shuaib A, Abou-Samra AB, Butler J, Freiberg MS.

Clin Infect Dis. 2017 Aug 15;65(4):557-565. doi: 10.1093/cid/cix359.

PMID:
28444148
4.

Diabetes mellitus increases the risk of hepatocellular carcinoma in treatment-naïve chronic hepatitis C patients in China.

Li X, Xu H, Gao Y, Pan M, Wang L, Gao P.

Medicine (Baltimore). 2017 Mar;96(13):e6508. doi: 10.1097/MD.0000000000006508.

5.

Performance of the Pooled Cohort atherosclerotic cardiovascular disease risk score in hepatitis C virus-infected persons.

Chew KW, Bhattacharya D, Horwich TB, Yan P, McGinnis KA, Tseng C, Freiberg MS, Currier JS, Butt AA.

J Viral Hepat. 2017 Oct;24(10):814-822. doi: 10.1111/jvh.12705. Epub 2017 Apr 10.

PMID:
28273386
6.

Hepatitis C virus and cardiovascular: A review.

Petta S.

J Adv Res. 2017 Mar;8(2):161-168. doi: 10.1016/j.jare.2016.06.001. Epub 2016 Jun 18. Review.

7.

The levels of monoamine neurotransmitters and measures of mental and emotional health in HCV patients treated with ledipasvir (LDV) and sofosbuvir (SOF) with or without ribavirin (RBV).

Golabi P, Elsheikh E, Karrar A, Estep JM, Younossi I, Stepanova M, Gerber L, Younossi ZM.

Medicine (Baltimore). 2016 Nov;95(46):e5066.

8.
9.

Commentary: Methamphetamine mediates immune dysregulation in a murine model of chronic viral infection.

Loftis JM.

Front Microbiol. 2015 Dec 23;6:1473. doi: 10.3389/fmicb.2015.01473. eCollection 2015. No abstract available.

10.

The epidemiology of substance use disorders in US Veterans: A systematic review and analysis of assessment methods.

Lan CW, Fiellin DA, Barry DT, Bryant KJ, Gordon AJ, Edelman EJ, Gaither JR, Maisto SA, Marshall BD.

Am J Addict. 2016 Jan;25(1):7-24. doi: 10.1111/ajad.12319. Epub 2015 Dec 22. Review.

11.

Hepatitis C virus as a systemic disease: reaching beyond the liver.

Gill K, Ghazinian H, Manch R, Gish R.

Hepatol Int. 2016 May;10(3):415-23. doi: 10.1007/s12072-015-9684-3. Epub 2015 Dec 10. Review.

12.

Changes in circulating lipids level over time after acquiring HCV infection: results from ERCHIVES.

Butt AA, Yan P, Simon TG, Chung RT, Abou-Samra AB; ERCHIVES study team.

BMC Infect Dis. 2015 Nov 11;15:510. doi: 10.1186/s12879-015-1268-2.

13.

HIV, Hepatitis C, and Abstinence from Alcohol Among Injection and Non-injection Drug Users.

Elliott JC, Hasin DS, Stohl M, Des Jarlais DC.

AIDS Behav. 2016 Mar;20(3):548-54. doi: 10.1007/s10461-015-1113-z.

14.

Short Communication: Coronary Heart Disease Risk by Framingham Risk Score in Hepatitis C and HIV/Hepatitis C-Coinfected Persons.

Chew KW, Bhattacharya D, McGinnis KA, Horwich TB, Tseng CH, Currier JS, Butt AA; ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans) Study.

AIDS Res Hum Retroviruses. 2015 Jul;31(7):718-22. doi: 10.1089/AID.2014.0284. Epub 2015 May 11.

15.

A window of opportunity: maximizing the effectiveness of new HCV regimens in the United States with the expansion of the Affordable Care Act.

Haley SJ, Kreek MJ.

Am J Public Health. 2015 Mar;105(3):457-63. doi: 10.2105/AJPH.2014.302327. Epub 2015 Jan 20.

16.

Virologic response and haematologic toxicity of boceprevir- and telaprevir-containing regimens in actual clinical settings.

Butt AA, Yan P, Shaikh OS, Freiberg MS, Lo Re V 3rd, Justice AC, Sherman KE; ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans) Study Team.

J Viral Hepat. 2015 Sep;22(9):691-700. doi: 10.1111/jvh.12375. Epub 2014 Dec 18.

17.

Liver fibrosis progression in hepatitis C virus infection after seroconversion.

Butt AA, Yan P, Lo Re V 3rd, Rimland D, Goetz MB, Leaf D, Freiberg MS, Klein MB, Justice AC, Sherman KE; ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans) Study Team.

JAMA Intern Med. 2015 Feb;175(2):178-85. doi: 10.1001/jamainternmed.2014.6502.

18.

Impact of hepatitis C seropositivity on the risk of coronary heart disease events.

Pothineni NV, Delongchamp R, Vallurupalli S, Ding Z, Dai Y, Hagedorn CH, Mehta JL.

Am J Cardiol. 2014 Dec 15;114(12):1841-5. doi: 10.1016/j.amjcard.2014.09.020. Epub 2014 Sep 28.

19.

Association between nonspecific severe psychological distress as an indicator of serious mental illness and increasing levels of medical multimorbidity.

Swartz JA, Jantz I.

Am J Public Health. 2014 Dec;104(12):2350-8. doi: 10.2105/AJPH.2014.302165. Epub 2014 Oct 16.

20.

Predictors of Mortality among United States Veterans with Human Immunodeficiency Virus and Hepatitis C Virus Coinfection.

Erqou S, Mohanty A, Murtaza Kasi P, Butt AA.

ISRN Gastroenterol. 2014 Apr 7;2014:764540. doi: 10.1155/2014/764540. eCollection 2014.

Supplemental Content

Support Center